Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adebrelimab + albumin-bound paclitaxel + cisplatin
- Development stage
- Phase 2
- Lead developer
- Hengrui Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
This neoadjuvant combination therapy regimen consists of adebrelimab, an anti-PD-L1 monoclonal antibody, combined with albumin-bound paclitaxel (nab-paclitaxel) and cisplatin. It is specifically being investigated for the treatment of resectable locally advanced thoracic esophageal squamous cell carcinoma (ESCC). Adebrelimab functions as an immune checkpoint inhibitor by targeting the PD-L1 pathway to restore anti-tumor immune responses. Albumin-bound paclitaxel is a microtubule-stabilizing agent that inhibits cell division, while cisplatin is a platinum-based chemotherapy that induces DNA damage. The regimen is currently being evaluated in a Phase 2 clinical trial (NCT06663059) sponsored by Tang-Du Hospital to compare the efficacy and safety of different treatment durations (2 vs. 4 cycles) prior to surgical resection.
- Brand names
- AdelyAbraxane
- Other names
- Adebrelimab + nab-paclitaxel + cisplatinAdebrelimab combined with albumin-bound paclitaxel and cisplatin
02
Targets
DNACD274 (Programmed cell death protein 1 ligand 1)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on adebrelimab + albumin-bound paclitaxel + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adebrelimab + albumin-bound paclitaxel + cisplatin.